Health conditions:-:Point in time:^Patient:-
FDA Approves Novavax COVID Vaccine After Delay, Limits Use to Smaller High-Risk Population
Novavax; FDA approval; COVID-19 vaccine; Nuvaxovid; restricted population; protein-based vaccine; older adults; underlying health conditions